New pill shows promise against rare brain cancer

NCT ID NCT04947319

Ongoing Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests tirabrutinib, a targeted cancer pill, in 119 people with primary central nervous system lymphoma (PCNSL), a rare brain cancer. Part A looks at patients whose cancer has returned or not responded to prior treatment. Part B tests tirabrutinib combined with chemotherapy in newly diagnosed patients. The goal is to see if the drug shrinks tumors and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirabrutinib (a targeted cancer drug taken as a pill)
What this could lead to: If successful, this could provide a new treatment option for primary CNS lymphoma, a rare brain cancer, potentially improving response rates.
What could go wrong: This is a mid-stage trial with a small number of participants. The drug may cause side effects or not work as well as hoped, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CNS LYMPHOMA REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Abramson Cancer Center University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
City of Hope Comprehensive Breast Cancer Center

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44106, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Dana-Farber Cancer Institute - Brigham & Women's Hospital

Boston, Massachusetts, 02215, United States
Duke University School of Medicine

Durham, North Carolina, 27705, United States
Georgetown University, Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20037, United States
Hackensack University Medical Center - John Theurer Cancer

Hackensack, New Jersey, 07601, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hillman Cancer Center, University of Pittsburgh

Pittsburgh, Pennsylvania, 15232, United States
Houston Methodist Research Institute (HMRI)

Houston, Texas, 77030, United States
Levine Cancer Center

Charlotte, North Carolina, 28204, United States
Lifespan Rhode Island Hospital

Providence, Rhode Island, 02903, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic- Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic- Phoenix

Phoenix, Arizona, 85054, United States
Memorial Sloan Kettering

New York, New York, 10022, United States
Moffitt Cancer Center- Miami

Pembroke Pines, Florida, 33028, United States
Orlando Health

Orlando, Florida, 32806, United States
Penn State Hershey Cancer Center

Hershey, Pennsylvania, 17033, United States
Piedmont Healthcare

Atlanta, Georgia, 30318, United States
Providence Health Cancer Center

Portland, Oregon, 97239, United States
Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI))

Buffalo, New York, 14263, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Stanford University

Palo Alto, California, 94304, United States
The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North

Kansas City, Missouri, 64154, United States
The University of Utah - Huntsman Cancer Institute (HCI)

Salt Lake City, Utah, 84112, United States
The University of Vermont - Fletcher Allen Health Care

Burlington, Vermont, 05401, United States
University Of Michigan

Ann Arbor, Michigan, 41809, United States
University of Alabama at Birmingham School of Medicine

Birmingham, Alabama, 35233, United States
University of California, Irvine

Irvine, California, 92868, United States
University of Colorado Denver

Aurora, Colorado, 80045, United States
University of Kentucky

Lexington, Kentucky, 40536, United States
University of Miami-Sylvester Cancer Center

Miami, Florida, 33136, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.